Novel Nondietary Therapies for Celiac DiseaseSummary

• Main Authors: Eaman Alhassan, Abhijeet Yadav, Ciaran P. Kelly, Rupa Mukherjee
• Format: Article
• Language: English
• Published: Elsevier 2019-01-01
• Series: Cellular and Molecular Gastroenterology and Hepatology
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352345X19300657

Celiac Disease (CeD) is defined as a chronic small intestinal immune-mediated enteropathy that is precipitated by exposure to dietary gluten in genetically predisposed individuals. CeD is one of the most common autoimmune disorders affecting around 1% of the population worldwide. Currently, the only acceptable treatment for CeD is strict, lifelong adherence to a gluten-free diet (GFD) which can often present a challenging task. A GFD alone is not sufficient to control symptoms and prevent mucosal damage that can result from unintentional gluten exposure. Moreover, long-term complications can occur in many patients. Consequently, there is an unmet need for non-dietary therapies for the management of CeD. Such therapies could serve as an adjunct to the GFD but eventually may replace it. This review will focus on and discuss non-dietary therapies currently in clinical development for the management of CeD. Methodology: We searched clinicaltrials.gov and PubMed to extract articles about celiac disease. We used keywords including, but not limited to, “celiac disease,” “non-dietary,” “therapeutics,” “pathophysiology,” “Endopeptidases,” “tight junction modulators,” “vaccine,” and “Nexvax2”. We focused mainly on articles that conducted pathophysiologic and therapeutic research in human trials. Keywords: Celiac Disease, Drug Therapy, Latiglutenase, Larazotide Acetate, Nexvax2, Necator americanus